Cupid share price movement
Cupid’s share price continued its upward movement, hitting a new high at ₹344.90, surging 6 per cent on the National Stock Exchange (NSE) in Wednesday’s intra-day deals in an otherwise subdued market.
What’s driving Cupid share price?
Driven by sustained momentum across its key business verticals and improved visibility across domestic and international markets, management revised its FY27 revenue guidance to ₹800 crore plus and net profit guidance to ₹250 crore plus.
Cupid said, the FY27 outlook has been revised upward, as the strong Q2FY27 business momentum was expected to continue and grow through Q3 & Q4 FY27, improved visibility across institutional and private markets, continued expansion of the domestic fast-moving consumer goods (FMCG) business, progress towards imminent operationalization of the Palava facility, and sustained growth across the company’s healthcare, and personal care portfolio.
Cupid guided revenue in the range of ₹725 crore to ₹750 crore and net profit between ₹210 crore and ₹225 crore, supported by a strong order book, sustained momentum across its international B2B healthcare business and continued expansion of its consumer healthcare & FMCG portfolio.
Cupid is engaged in the manufacturing and marketing of male and female condoms, water-based personal lubricants, IVD kits and a growing portfolio of Consumer Healthcare & FMCG products.
Cupid’s Consumer Healthcare & FMCG portfolio includes fragrance products (Eau De Parfums, Deodorants and Pocket Perfumes), personal care products (Hair Removal Sprays, Face Wash, Hair & Body Oils, Toilet Sanitizers), in-vitro diagnostic (IVD) kits, personal lubricants and other consumer healthcare offerings.
Cupid – Outlook
The global condom market continues to grow steadily, driven by rising awareness of HIV and other sexually transmitted infections, family-planning programmes and expanding retail and e-commerce access. The global condom market is expected to grow at a compound annual growth rate (CAGR) of about 8.7 per cent between FY23-30. The Asia-Pacific region is the largest market, accounting for roughly half of global revenue, and latex remains the dominant material. As one of the few fully integrated manufacturers supplying both public-health programmes and private brands, Cupid said in its FY26 annual report that the company is well placed to participate in this growth across geographies and channels.
Rapid diagnostics remain a large and growing opportunity. In India, IMARC estimated the IVD market at approximately $5.3 billion in 2024, growing to around $10.0 billion by 2033. Structural drivers include the rising incidence of chronic and infectious disease, growing health awareness, the expansion of diagnostic access into smaller towns and rural areas, and continued government focus on public health, the company said.
